Senator Elizabeth Warren, during a Senate Banking Committee nomination hearing in Washington, D.C.
Andrew Harrer | Bloomberg | Getty Images
In a letter to viewed by CNBC, the Massachusetts Democrat urged the federal oversight board tasked with monitoring how Covid-19 relief funding is spent to investigate the decision-making behind the loan.
Warren first questioned the motives of the U.S. International Development Finance Corporation, a new federal foreign investment agency that has been tasked by President Donald Trump to help find ways to rebuild the national stockpile of medical supplies.
“The fiasco surrounding the decision to offer, then revoke, the Kodak loan also raises larger questions about corruption, nepotism, and mismanagement in the Trump Administration’s response to COVID-19,” Warren wrote to Michael Horowitz, the acting chair of the Pandemic Response Accountability Committee.
“It is not at all clear why President Trump, in his Executive Order, chose to give the DFC … this new loan authority — but the mismanagement of the Kodak loan raises new concerns that it may be fundamentally unsuited to the task.”
The letter from Warren came just weeks after the Trump administration announced that it planned to award Kodak a $765 million loan through the DFC so that the company could produce ingredients used in drugs.
But Kodak, which has struggled to survive after digital cameras overtook its once-dominant film business, may not be the best company equipped to manufacture pharmaceuticals. It’s for that reason, and in light of unprecedented lobbying by the company, that the decision to make the loan ought to be investigated, Warren argued.
“DFC provided this taxpayer-funded loan to produce an unproven drug to Kodak, a company that had no pharmaceutical manufacturing experience, through an opaque process and after an extensive and unprecedented lobbying effort by the company,” Warren, a member of the Senate Banking Committee, wrote.
“Then, it got worse,” she continued, referring to questionable stock purchases made in the days leading up to the loan’s public announcement.
On July 27, a day before Kodak and Trump announced the loan, shares of the film pioneer soared nearly 25% with trading volumes far exceeding those in previous sessions. The stock had plateaued around $2 per share for months but spiked as high as $60 per share the day after the deal.
The Securities and Exchange Commission has since opened an insider trading investigation and the Trump administration has since revoked the loan.
“The net result has been a waste of time, money, and resources, no progress whatsoever in the effort to mitigate the coronavirus disease 2019 (COVID-19) pandemic, and a host of questions about how and why the Trump Administration is handing out taxpayer funds and who is benefitting from these expenditures,” Warren wrote.
Condemnation of the dubious trading and executive purchases isn’t confined to Democrats. White House trade advisor Peter Navarro blasted Kodak executives on Monday for their handling of the loan announcement.
“Based on what I’m seeing, what happened at Kodak was probably the dumbest decisions made by executives in corporate history,” Navarro told CNBC earlier this week.
“You can’t fix ‘stupid,'” he added. “You can’t even anticipate that degree of stupidity.”
Subscribe to CNBC PRO for exclusive insights and analysis, and live business day programming from around the world.